Inactive precursor forms of PSA (pPSA) have been identified to exist in
serum and tissues of patients with prostate cancer. Antibodies specific
for pPSA are provided. Methods for detecting inactive precursors of PSA
in human physiological fluid and tissues are also provided, as well as
diagnostic kits and methods useful in the diagnosis and management of
prostate cancer.